T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 23, 2007

Primary Completion Date

September 25, 2014

Study Completion Date

April 16, 2015

Conditions
LeukemiaLymphomaMultiple MyelomaPlasma Cell NeoplasmMyelodysplastic Syndromes
Interventions
BIOLOGICAL

umbilical cord blood transplantation

Infusion of umbilical cord blood

DRUG

Allopurinol

Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.

DRUG

fludarabine phosphate

40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2

DRUG

Cyclophosphamide

50 mg/kg intravenous over 2 hours on Day -6

RADIATION

Total body irradiation

200 cGy on Day -1

BIOLOGICAL

Treg infusion

Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.

DRUG

Sirolimus

Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00602693 - T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Biotech Hunter | Biotech Hunter